Laura Vangeel1,2, Melissa Benoit1,2, Yannick Miron3, Paul E Miller3, Katrien De Clercq1,2,4, Patrick Chaltin5, Catherine Verfaillie6, Joris Vriens4, Thomas Voets1,2. 1. Laboratory of Ion Channel Research, VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium. 2. Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium. 3. AnaBios, San Diego, California. 4. Laboratory of Endometrium, Endometriosis & Reproductive Medicine, Department of Development and Regeneration, G-PURE, KU Leuven, Leuven, Belgium. 5. Center for Drug Design and Discovery, Bio-Incubator 2, Heverlee, Belgium. 6. Department of Development and Regeneration, Stem Cell Institute, KU Leuven, Leuven, Belgium.
Abstract
BACKGROUND AND PURPOSE: The transient receptor potential (TRP) ion channel TRPM3 functions as a noxious heat sensor, plays a key role in acute pain sensation and inflammatory hyperalgesia in rodents. Despite its potential as a novel analgesic drug target, little is known about the expression, function and modulation in the humans. EXPERIMENTAL APPROACH: We studied TRPM3 in freshly isolated human dorsal root ganglion (hDRG) neurons and human stem cell-derived sensory (hSCDS) neurons. Expression was analysed at the mRNA level using RT-qPCR. Channel function was assessed using Fura-2-based calcium imaging and whole-cell patch-clamp recordings. KEY RESULTS: TRPM3 was detected at the mRNA level in both hDRG and hSCDS neurons. The TRPM3 agonists pregnenolone sulphate (PS) and CIM0216 evoked robust intracellular Ca2+ responses in 52% of hDRG and 58% of hSCDS neurons. Whole-cell patch-clamp recordings in hSCDS neurons revealed pregnenolone sulphate (PS)- and CIM0216-evoked currents exhibiting the characteristic current-voltage relation of TRPM3. PS-induced calcium responses in hSCDS neurons were reversed in a dose-dependent manner by the flavonoid isosakuranetin and by antiseizure drug primidone. Finally, the μ-opioid receptor agonist DAMGO and the GABAB receptor agonist baclofen inhibited PS-evoked TRPM3 responses in a subset of hSCDS neurons. CONCLUSION AND IMPLICATIONS: These results provide the first direct evidence of functional expression of the pain receptor TRPM3 in human sensory neurons, largely mirroring the channel's properties observed in mouse sensory neurons. hSCDS neurons represent a valuable and readily accessible in vitro model to study TRPM3 regulation and pharmacology in a relevant human cellular context.
BACKGROUND AND PURPOSE: The transient receptor potential (TRP) ion channel TRPM3 functions as a noxious heat sensor, plays a key role in acute pain sensation and inflammatory hyperalgesia in rodents. Despite its potential as a novel analgesic drug target, little is known about the expression, function and modulation in the humans. EXPERIMENTAL APPROACH: We studied TRPM3 in freshly isolated human dorsal root ganglion (hDRG) neurons and human stem cell-derived sensory (hSCDS) neurons. Expression was analysed at the mRNA level using RT-qPCR. Channel function was assessed using Fura-2-based calcium imaging and whole-cell patch-clamp recordings. KEY RESULTS: TRPM3 was detected at the mRNA level in both hDRG and hSCDS neurons. The TRPM3 agonists pregnenolone sulphate (PS) and CIM0216 evoked robust intracellular Ca2+ responses in 52% of hDRG and 58% of hSCDS neurons. Whole-cell patch-clamp recordings in hSCDS neurons revealed pregnenolone sulphate (PS)- and CIM0216-evoked currents exhibiting the characteristic current-voltage relation of TRPM3. PS-induced calcium responses in hSCDS neurons were reversed in a dose-dependent manner by the flavonoid isosakuranetin and by antiseizure drug primidone. Finally, the μ-opioid receptor agonist DAMGO and the GABAB receptor agonist baclofen inhibited PS-evoked TRPM3 responses in a subset of hSCDS neurons. CONCLUSION AND IMPLICATIONS: These results provide the first direct evidence of functional expression of the pain receptor TRPM3 in human sensory neurons, largely mirroring the channel's properties observed in mouse sensory neurons. hSCDS neurons represent a valuable and readily accessible in vitro model to study TRPM3 regulation and pharmacology in a relevant human cellular context.
Authors: Gareth T Young; Alex Gutteridge; Heather DE Fox; Anna L Wilbrey; Lishuang Cao; Lily T Cho; Adam R Brown; Caroline L Benn; Laura R Kammonen; Julia H Friedman; Magda Bictash; Paul Whiting; James G Bilsland; Edward B Stevens Journal: Mol Ther Date: 2014-05-15 Impact factor: 11.454
Authors: Laura Vangeel; Melissa Benoit; Yannick Miron; Paul E Miller; Katrien De Clercq; Patrick Chaltin; Catherine Verfaillie; Joris Vriens; Thomas Voets Journal: Br J Pharmacol Date: 2020-03-05 Impact factor: 8.739
Authors: Wout Backaert; Brecht Steelant; Peter W Hellings; Karel Talavera; Laura Van Gerven Journal: Curr Allergy Asthma Rep Date: 2021-03-18 Impact factor: 4.806
Authors: Harold A Silverman; Adrian Chen; Nigel L Kravatz; Sangeeta S Chavan; Eric H Chang Journal: Front Immunol Date: 2020-10-23 Impact factor: 7.561
Authors: Balázs Kelemen; Silvia Pinto; Nawoo Kim; Erika Lisztes; Martin Hanyicska; Anita Vladár; Attila Oláh; Zsófia Pénzes; Brian Shu; Joris Vriens; Tamás Bíró; Tibor Rohács; Thomas Voets; Balázs István Tóth Journal: Biochem Pharmacol Date: 2020-10-29 Impact factor: 6.100